Neonatal and Pediatric Fluid Therapy: Special Considerations for Puppies and Kittens

Neonatal puppies and kittens (birth to 2 weeks) and pediatric patients (2-12 weeks) differ fundamentally from adult patients in several ways that directly impact fluid therapy decisions.

Higher total body water (TBW): Neonates have approximately 80% TBW versus 60% in adults, with a greater proportion in the extracellular compartment. This means they have a larger fluid "reservoir" but also higher obligatory water losses through immature skin and respiratory tract evaporation.

Immature renal function: The neonatal kidney has a reduced glomerular filtration rate (GFR) and limited concentrating ability (maximum urine specific gravity approximately 1.020 in the first week). Neonates cannot conserve water effectively during dehydration and cannot excrete excess water rapidly during over-hydration. This narrow margin of safety makes precise fluid calculations critical.

Limited glycogen stores: Neonatal hepatic glycogen is depleted within 12-24 hours of fasting. Hypoglycemia (blood glucose <40 mg/dL) develops rapidly and can cause seizures, hypothermia, and death. All fluid therapy plans for neonates must address glucose supplementation.

Higher metabolic rate and surface-area-to-mass ratio: Neonates have a higher metabolic rate per kilogram and proportionally greater surface area, leading to increased insensible fluid losses and caloric demands.

Vascular access in neonates presents unique challenges. Their tiny vessel size, fragile veins, and limited subcutaneous tissue make traditional IV catheterization difficult. The choice of fluid administration route depends on patient size, hemodynamic status, and available equipment.

Intravenous (IV): The gold standard for critically ill neonates. The jugular vein is often the most accessible site in very small patients. Use 24-gauge catheters and consider surgical cutdown if percutaneous access fails. Syringe pumps are essential for delivering the small, precise volumes required.

Intraosseous (IO): An excellent alternative when IV access cannot be established quickly. The proximal femur (trochanteric fossa), proximal tibia, and proximal humerus are suitable sites. An 18-22 gauge hypodermic or spinal needle can be used. IO access allows administration of any fluid, blood product, or medication that can be given IV, and flow rates are comparable.

Subcutaneous (SC): Appropriate only for mildly dehydrated, hemodynamically stable neonates. Absorption is unreliable in hypothermic or peripherally vasoconstricted patients. Limit volumes to 10-15 mL per site, and always warm fluids to body temperature before administration.

Hypoglycemia is a common and rapidly fatal complication in neonatal patients. Blood glucose should be monitored every 2-4 hours in critically ill neonates using a point-of-care glucometer. Target blood glucose is 80-150 mg/dL.

For maintenance fluids, add dextrose to achieve a 2.5-5% solution. To make 2.5% dextrose from 50% dextrose stock: add 50 mL of 50% dextrose to 950 mL of the chosen crystalloid (or 5 mL per 100 mL bag). For 5% dextrose: add 100 mL of 50% dextrose to 900 mL of crystalloid.

For acute hypoglycemia (blood glucose <40 mg/dL or clinical signs): administer a 0.5-1 mL/kg bolus of 12.5% dextrose IV slowly over 5 minutes, then follow with a dextrose-containing maintenance fluid infusion. Never administer 50% dextrose undiluted to neonates as it causes phlebitis, tissue necrosis if extravasated, and rebound hypoglycemia.

Hypothermia is the "silent killer" in neonatal medicine. Neonates lack effective shivering reflex (develops around 6 days of age), have minimal subcutaneous fat for insulation, and have a large surface-area-to-mass ratio. Core body temperature drops rapidly when neonates are separated from the dam, placed on cold surfaces, or administered room-temperature fluids.

All fluids for neonatal administration must be warmed to 37-39°C (98.6-102.2°F). Room-temperature crystalloid administered to a 200 g kitten can drop core temperature by 1-2°C. Use fluid warmers, warm water baths, or incubators to maintain fluid temperature throughout administration.

During resuscitation, simultaneously address warming: incubator set to 30-32°C for the first week of life, warm water blankets, and warm the inspired air if providing supplemental oxygen. Monitor rectal temperature every 30-60 minutes.

Fading puppy/kitten syndrome describes neonates that are initially vigorous but progressively decline in the first 1-2 weeks of life. Common causes include bacterial sepsis (often from environmental contamination of the umbilicus), viral infections (parvovirus, herpesvirus), neonatal isoerythrolysis, congenital defects, hypothermia, and inadequate nutrition.

The fluid therapy approach for a fading neonate follows a systematic protocol:

• Step 1 — Warm first: Correct hypothermia slowly (over 1-3 hours) before giving fluids. Cold neonates cannot absorb or metabolize fluids effectively.
• Step 2 — Check glucose: Treat hypoglycemia with 12.5% dextrose bolus (0.5-1 mL/kg IV/IO).
• Step 3 — Rehydrate: Calculate deficit (body weight × % dehydration × 10 = mL) and replace over 6-12 hours using warmed crystalloid with 2.5% dextrose.
• Step 4 — Maintain: Start maintenance fluids at 120-180 mL/kg/day with dextrose supplementation.
• Step 5 — Treat underlying cause: Broad-spectrum antibiotics if sepsis suspected, plasma if coagulopathic.